Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-121/TEZ/D-IVA in Cystic Fibrosis Subjects 1 Through 11 Years of Age
NCT05422222Phase 3Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of vanzacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Jun 2022; status: active, not recruiting.
02
Drugs
vanzacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05422222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05422222.